EQS Group-News: Zur Rose Group AG / Key word(s): AGMEGM
2020 Annual General Meeting of Zur Rose Group AG
Shareholders adopt all proposals
The 27th Annual General Meeting of Shareholders of Zur Rose Group AG was held today in Zurich. Owing to the exception circumstances related to the coronavirus, the meeting took place without shareholders being physically present. A total of 4,021,346 shareholder votes, equivalent to 41.7 per cent of the share capital and 72.3 per cent of the shares entitled to vote, were represented by the independent proxy. The Board of Directors would like to thank all those who exercised their rights as shareholders in this way.
The shareholders approved the Management Report, the Annual Financial Statements and Consolidated Financial Statements for 2019 and the appropriation of retained earnings and ratified the actions taken by the Board of Directors and Group Management during the year. The Chairman of the Board of Directors, all members of the Board of Directors and all members of the Compensation Committee were confirmed in office for a further term of one year. The AGM approved the requested maximum amounts of compensation for the members of the Board of Directors and Group Management for financial years 2019, 2020 and 2021. The Compensation Report for financial year 2019 was also endorsed in a consultative vote. Ernst & Young AG were confirmed as the statutory auditor and Fürer Partner Advocaten KIG as the independent proxy for another term of one year.
Shareholders also approved the proposal to create authorised share capital with a nominal value of CHF 26,219,910, equivalent to 10 per cent of the registered share capital. As announced on 20 April 2020, the motion to create additional conditional capital was withdrawn.
The minutes of the AGM (in German) with the detailed voting results are available at "www.zurrosegroup.com > Investors & Media > General Meeting of Shareholders" from 24 April 2020.
Investors and analyst contact
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and has around seven million active customers in core European markets.
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1028729|
|End of News||EQS Group News Service|